{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=serum+sample&page=71", "query": { "intervention": "serum sample", "page": 71 }, "page_size": 10 }, "pagination": { "page": 71, "page_size": 10, "total_count": 8380, "total_pages": 838, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=serum+sample&page=72&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=serum+sample&page=70&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-29T09:10:02.390Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06204614", "title": "Drug Screening Using IMD in Bladder Cancer", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Muscle Invasive Bladder Urothelial Carcinoma" ], "interventions": [ { "name": "Implantable Micro-Device", "type": "DEVICE" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Avelumab", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Vinblastine", "type": "DRUG" }, { "name": "Gemcitabine/Cisplatin I", "type": "DRUG" }, { "name": "Methotrexate/Vinblastine/Doxorubicin/Cisplatin/Avelumab", "type": "DRUG" }, { "name": "Gemcitabine/Cisplatin II", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Gemcitabine/Carboplatin", "type": "DRUG" }, { "name": "Methotrexate/Vinblastine/Doxorubicin/Cisplatin", "type": "DRUG" }, { "name": "Gemcitabine/Cisplatin/Nivolumab", "type": "DRUG" }, { "name": "Erdafitinib", "type": "DRUG" }, { "name": "Paclitaxel/Docetaxel/Ifosfamide", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Gemcitabine/Carboplatin/Nivolumab", "type": "DRUG" }, { "name": "Enfortumab", "type": "DRUG" }, { "name": "Sacituzumab", "type": "DRUG" } ], "intervention_types": [ "DEVICE", "DRUG" ], "sponsor": "Brigham and Women's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 18, "start_date": "2024-06-14", "completion_date": "2028-08-01", "has_results": false, "last_update_posted_date": "2026-05-18", "last_synced_at": "2026-10-29T09:10:02.390Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06204614" }, { "nct_id": "NCT00203905", "title": "A Study of Chemoradiotherapy for Intermediate Stage/Selected Stage IV Cancers of the Head and Neck", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Head and Neck Cancer" ], "interventions": [ { "name": "5-Fluorouracil, Hydroxyurea-[FHX], Bevacizumab", "type": "DRUG" }, { "name": "5-Fluorouracil, Hydroxyurea-[FHX]", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2004-01", "completion_date": "2008-11", "has_results": false, "last_update_posted_date": "2014-01-17", "last_synced_at": "2026-10-29T09:10:02.390Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00203905" }, { "nct_id": "NCT00066846", "title": "Bevacizumab Plus Fluorouracil and Leucovorin in Treating Patients With Locally Advanced or Metastatic Stage IV Colorectal Cancer That Has Progressed After Standard Chemotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "bevacizumab", "type": "BIOLOGICAL" }, { "name": "fluorouracil", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2003-08", "completion_date": "2007-07", "has_results": false, "last_update_posted_date": "2013-06-20", "last_synced_at": "2026-10-29T09:10:02.390Z", "location_count": 33, "location_summary": "Anchorage, Alaska • Los Angeles, California • Aurora, Colorado + 27 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT00066846" }, { "nct_id": "NCT05308446", "title": "Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Colon Adenocarcinoma", "Metastatic Rectal Adenocarcinoma", "Stage III Colon Cancer AJCC v8", "Stage III Rectal Cancer AJCC v8", "Stage IV Colon Cancer AJCC v8", "Stage IV Rectal Cancer AJCC v8", "Unresectable Colon Adenocarcinoma", "Unresectable Rectal Adenocarcinoma" ], "interventions": [ { "name": "Cetuximab", "type": "BIOLOGICAL" }, { "name": "Encorafenib", "type": "DRUG" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 86, "start_date": "2022-07-19", "completion_date": "2027-06-01", "has_results": false, "last_update_posted_date": "2026-07-08", "last_synced_at": "2026-10-29T09:10:02.390Z", "location_count": 282, "location_summary": "Goodyear, Arizona • Carmichael, California • Dublin, California + 223 more", "locations": [ { "city": "Goodyear", "state": "Arizona" }, { "city": "Carmichael", "state": "California" }, { "city": "Carmichael", "state": "California" }, { "city": "Dublin", "state": "California" }, { "city": "Elk Grove", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05308446" }, { "nct_id": "NCT00796705", "title": "Switching Anti-TNF-Alpha Agents in Rheumatoid Arthritis (RA)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Adalimumab", "type": "DRUG" }, { "name": "Adalimumab placebo", "type": "DRUG" }, { "name": "Etanercept", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2008-11", "completion_date": "2010-10", "has_results": true, "last_update_posted_date": "2012-10-04", "last_synced_at": "2026-10-29T09:10:02.390Z", "location_count": 16, "location_summary": "Birmingham, Alabama • Palo Alto, California • New Haven, Connecticut + 13 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Palo Alto", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00796705" }, { "nct_id": "NCT03573986", "title": "Pilot Study of 18F-FMISO PET/CT and MRI Imaging to Explore Tissue Hypoxia and Arteriovenous Shunting in Subjects With Recurrent Glioblastoma Before and After Bevacizumab Treatment", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Glioblastoma" ], "interventions": [ { "name": "[18F]fluoromisonidazole", "type": "BIOLOGICAL" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "positron emission tomography (PET/CT).", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION" ], "sponsor": "Abramson Cancer Center at Penn Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2018-04-18", "completion_date": "2020-01-14", "has_results": false, "last_update_posted_date": "2020-02-17", "last_synced_at": "2026-10-29T09:10:02.390Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03573986" }, { "nct_id": "NCT00041470", "title": "Navelbine, Taxol, Herceptin and Neupogen in Stage IV Breast Cancer: A Phase I - II Trial", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Vinorelbine", "type": "DRUG" }, { "name": "Herceptin", "type": "DRUG" }, { "name": "Filgrastim", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 38, "start_date": "2001-03", "completion_date": "2008-08", "has_results": true, "last_update_posted_date": "2017-07-17", "last_synced_at": "2026-10-29T09:10:02.390Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00041470" }, { "nct_id": "NCT00606905", "title": "Intravenous Immunoglobulin (IVIG) for Treatment of Unexplained Secondary Recurrent Miscarriage", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Miscarriage, Recurrent", "Abortion, Habitual" ], "interventions": [ { "name": "Gamimune N or Gamunex 10%", "type": "BIOLOGICAL" }, { "name": "normal saline", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "FEMALE", "summary": "18 Years to 45 Years · Female only" }, "enrollment_count": 82, "start_date": "1999-11", "completion_date": "2010-01", "has_results": true, "last_update_posted_date": "2012-10-08", "last_synced_at": "2026-10-29T09:10:02.390Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00606905" }, { "nct_id": "NCT01633970", "title": "A Study of Atezolizumab Administered in Combination With Bevacizumab and/or With Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "5-FU", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 240, "start_date": "2012-07-11", "completion_date": "2020-02-26", "has_results": false, "last_update_posted_date": "2020-10-08", "last_synced_at": "2026-10-29T09:10:02.390Z", "location_count": 11, "location_summary": "Aurora, Colorado • New Haven, Connecticut • Washington D.C., District of Columbia + 6 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01633970" }, { "nct_id": "NCT06834373", "title": "Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Large B-Cell Lymphoma With IRF4 Rearrangement", "Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma", "Recurrent ALK-Positive Large B-Cell Lymphoma", "Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type", "Recurrent Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation", "Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type", "Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified", "Recurrent EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified", "Recurrent Grade 3b Follicular Lymphoma", "Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements", "Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified", "Recurrent Intravascular Large B-Cell Lymphoma", "Recurrent Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type", "Recurrent Primary Mediastinal Large B-Cell Lymphoma", "Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma", "Recurrent Transformed Non-Hodgkin Lymphoma", "Refractory Aggressive B-Cell Non-Hodgkin Lymphoma", "Refractory ALK-Positive Large B-Cell Lymphoma", "Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type", "Refractory Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation", "Refractory Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type", "Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified", "Refractory EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified", "Refractory Grade 3b Follicular Lymphoma", "Refractory High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements", "Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified", "Refractory Intravascular Large B-Cell Lymphoma", "Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type", "Refractory Primary Mediastinal Large B-Cell Lymphoma", "Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma", "Refractory Transformed Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Chimeric Antigen Receptor T-Cell Therapy", "type": "BIOLOGICAL" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Golcadomide", "type": "DRUG" }, { "name": "Leukapheresis", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Rituximab", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL", "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2025-04-02", "completion_date": "2028-09-09", "has_results": false, "last_update_posted_date": "2026-10-20", "last_synced_at": "2026-10-29T09:10:02.390Z", "location_count": 7, "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Albert Lea, Minnesota + 4 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Albert Lea", "state": "Minnesota" }, { "city": "Mankato", "state": "Minnesota" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT06834373" } ] }